Flucar (oseltamivir) cream 15 g.

$8.00

Manufacturer: Ukraine

Treatment of influenza Flukap is indicated for adults and children from 1 year of age who have flu-like symptoms during the circulation of the flu virus. Effectiveness was demonstrated when treatment was started within two days of the onset of symptoms. Prevention of influenza Prevention of influenza in adults and children older than 1 year after contact with a person with clinically diagnosed influenza during the circulation of the flu virus. The appropriate use of Flukap for flu prevention should be determined on a case-by-case basis, taking into account the circumstances and the group of patients who need protection. In exceptional situations (for example, if there is a discrepancy between the circulating influenza virus and the influenza virus that was vaccinated, and during a pandemic), seasonal prevention can be performed for children aged 1 year and older. The use of the drug Flucap does not replace the flu Vaccines.

Category:

Description

Flucar Storage
active substance: fluocinolone acetonide;

1 g of cream contains 1 mg of fluocinolone acetonide;

Excipients: methyl parahydroxybenzoate (E 218), propylene glycol, white soft paraffin, mineral oil, paraffin, cetostearyl alcohol (type A) emulsified, disodium edetate, purified water.

Flucar Dosage form
Cream.

Basic physical and chemical properties: homogeneous white cream.

Flucar Pharmacotherapeutic group
Corticosteroids for use in dermatology. Simple corticosteroid drugs. Active corticosteroids (group III). Fluocinolone acetonide.

ATX code D07A C04.

Pharmacodynamics
Flutzar®-Darnitsa contains a synthetic fluorinated corticosteroid for external use. The mechanism of action is to reduce inflammatory processes by inhibiting the production of prostaglandins and leukotrienes due to inhibition of phospholipase A2 activity and reducing the release of arachidonic acid from cell membrane phospholipids.

Glucocorticosteroids inhibit the release of cytokines (interleukins 1 and 2 and gamma-interferon) from lymphocytes and macrophages, inhibit the release of inflammatory mediators by eosinophils, reduce the metabolism of arachidonic acid. Reduce vascular permeability, inhibit phagocytosis.

The antiallergic effect is to suppress the development of local allergic reactions. Due to the local vasoconstrictor effect, the drug reduces protein synthesis, collagen deposition, accelerates the breakdown of proteins in the skin and inhibits proliferative processes. Inhibits the proper division of cells, so it is used in the treatment of keloids and psoriasis.

By stimulating steroid receptors, the drug promotes the formation of lipocortin proteins that have anti-edematous activity.

Fluocinolone acetonide has a pronounced anti-inflammatory, anti-allergic, anti-exudative and antipruritic effect. Even in small concentrations it has a rapid anti-inflammatory and antipruritic effect.

Pharmacokinetics
Fluocinolone acetonide easily penetrates the skin through its outer stratum corneum.

Absorption of fluocinolone acetonide through the skin is enhanced by applying to sensitive skin areas of anatomical folds of the body and face, as well as on skin with damaged epidermis or inflammation. The use of an occlusive dressing causes an increase in skin temperature and humidity, which also leads to increased absorption of fluocinolone acetonide. In addition, absorption is enhanced by frequent use of the drug and on large areas of skin.

Absorption through the skin is higher in children than in adults.

After absorption (absorption not more than 1%) through the skin, the drug is metabolized mainly in the liver.

Insignificant absorption of the drug does not have a systemic effect and does not inhibit the function of the adrenal cortex. The use of occlusive dressings significantly increases bioavailability, which may lead to the development of general resorptive effects characteristic of fluorinated glucocorticosteroids.

Excreted in the urine and in small quantities in the bile, in the form of conjugates of glucuronides in unchanged state.

Indication
Short-term local treatment of acute and severe non-infectious skin diseases (dry forms), scalp psoriasis, seborrheic dermatitis, herpes zoster.

Contraindication
Hypersensitivity to the active substance or to other components of the medicinal product; infectious skin diseases (bacterial, viral, fungal), including skin manifestations of syphilis, tuberculosis of the skin, pyoderma, chickenpox, herpes, actinomycosis, blastomycosis, sporotrichosis; pink and common acne; diaper dermatitis; perioral dermatitis; perianal and genital itching; skin neoplasms, skin tumors; naevus; atheroma; hemangioma; xanthoma; wounds and ulcers of the skin, wounds on the application sites; numerous psoriatic plaques, trophic leg ulcers associated with varicose veins; erosive-ulcerative lesions of the digestive tract. Do not use after preventive vaccinations.